Current Edition

Securing the Global Pharmaceutical Supply Chain Against the Threat of Counterfeit Drugs

According to the WHO, the prevalence of spurious, falsely-labelled, falsified, or counterfeit medicines, or SFFC medicines as they are known ? medicines that are deliberately and fraudulently produced, packaged and/or mislabelled ? is a growing trend worldwide which threatens both patient safety and public confidence in the health systems and regulatory bodies designed to provide oversight and control. Dr Rudiger Lomb of World Courier tells us what pharmaceutical professionals can do to ensure that their organisations and the patients they serve are not impacted by counterfeit drugs.